Highest-materiality recent filing
Genprex regains compliance with Nasdaq minimum bid price requirement
Nasdaq Panel notified Genprex on Aug 4, 2026 that it has regained compliance with the $1.00 minimum bid price rule.
Genprex collaborates with Roche Diagnostics to validate TROP2/PTEN biomarkers for NSCLC
Collaboration with Roche Diagnostics to validate TROP2 and PTEN biomarkers for patient selection in NSCLC clinical trials.
Genprex receives Nasdaq exception to continue listing; must meet $1 bid price by July 29, 2026
Nasdaq panel granted exception to continue listing; must demonstrate $1.00 minimum bid price compliance by July 29, 2026 and maintain through Dec 7, 2026.
Genprex files 1:22 reverse stock split to address Nasdaq bid price deficiency; faces delisting risk
Reverse stock split at 1:22 ratio effective July 16, 2026; shares outstanding to reduce from ~11.1M to ~505K.
Stockholders approved amendment to certificate of incorporation to effect reverse stock split at ratio from 1:5 to 1:50, at board's discretion before Dec 31, 2027.
Genprex receives Nasdaq delisting notice due to sub-$1 bid price; ineligible for compliance period
Nasdaq staff determined on June 10, 2026 to delist GNPX due to bid price below $1.00 for 30 consecutive days.
Genprex reports positive predictive biomarker data for Reqorsa in NSCLC at ASCO 2026
In NSCLC patients, Trop-2 H-score >100 and PTEN H-score <100 correlated with prolonged PFS (p=0.05, p=0.03).
Genprex diabetes gene therapy GPX-002 reverses hyperglycemia in T2D mouse model
Preclinical data presented at ASGCT 2026 showed GPX-002 reversed hyperglycemia in Type 2 diabetic mice within 4 weeks.
Genprex' GPX-002 reverses hyperglycemia in T2D mouse models; data at ASGCT 2026
GPX-002 (Pdx1/MafA gene therapy) reversed hyperglycemia in HFD-induced T2D mouse models within 4 weeks post-treatment.
Genprex inks new MD Anderson SRA for Reqorsa biomarkers; trial updates show partial responses
New Sponsored Research Agreement with UT MD Anderson to study TROP2 and PTEN as biomarkers for Reqorsa in NSCLC and SCLC.
Genprex announces positive preclinical data for Reqorsa at AACR 2026
TROP2 and PTEN identified as potential biomarkers of primary resistance to TUSC2 gene therapy; 50% of NSCLC cell lines resistant.
Genprex wins Japanese and European patent grants for REQORSA combos; Acclaim-3 update
Japanese Patent Office issued favorable Appeal Decision to grant patent for REQORSA + PD-L1 antibodies.
Initiated preclinical research in Type 2 diabetic animal models; in vivo proof-of-concept showed normalized glucose levels.
First T2D NHP received intraductal AAV infusion of GPX-002 (Pdx1+MafA) and showed normal glucose tolerance test at 7 months.
Genprex believes it now meets Nasdaq minimum equity requirement; Panel yet to rule
Company raised proceeds from registered direct offerings (Oct 24 and 29, 2025), ATM with H.C. Wainwright, and equity line with Lincoln Park to boost equity.
Genprex (GNPX) regains Nasdaq bid price compliance, gets equity exception to Dec 31
Nasdaq Panel confirmed Genprex regained compliance with Minimum Bid Price requirement ($1.00).
Genprex files to sell up to $75M in common stock via ATM with H.C. Wainwright
Filed Nov 21, 2025 prospectus supplement for up to $75M of common stock under existing ATM agreement.
Genprex granted US patent for REQORSA plus PD-L1 antibody combo through 2037
USPTO patent covers REQORSA gene therapy combined with PD-L1 antibodies like Tecentriq, securing exclusivity to 2037.
Genprex raises ~$3.4M in registered direct offering plus up to $6.6M from warrant exercise
Offering: 377,780 shares at $9.00/share; gross proceeds ~$3.4M before fees.
Issued 243,622 shares at $11.21/sh for ~$2.7M gross proceeds; net ~$2.3M after fees.
Genprex reports positive preclinical data for Reqorsa in ALK+ NSCLC at AACR-NCI-EORTC conference
Reqorsa plus alectinib shrank tumors by 79% vs 60% with alectinib alone in mouse xenograft model.
Genprex granted Nasdaq exception through Oct 31, 2025; 1-for-50 reverse stock split effective Oct 21
Nasdaq Panel exception to demonstrate compliance with $1.00 bid price and $2.5M stockholders' equity until Oct 31, 2025; Panel may extend to Feb 9, 2026.
Genprex faces Nasdaq delisting for both equity and bid price non-compliance; hearing requested
Stockholders' equity of $1.39M as of June 30, 2025, below Nasdaq's $2.5M minimum requirement.
Genprex stockholders approve reverse split (1:10-1:50), 6.5M new shares for equity plan
Approved Amended & Restated 2018 Equity Plan, adding 6,500,000 shares and extending term to June 30, 2035.
Genprex reports positive preclinical data for GPX-002 using lipid nanoparticle delivery at ADA 2025
Nine LNPs tested; two were highly efficient in transfecting α- and β-cells in isolated mouse islets.
Genprex secures $12.5M equity line with Lincoln Park; provides clinical trial updates
Entered purchase agreement for up to $12.5M in common stock; issued 1,186,859 commitment shares to Lincoln Park.
Genprex regains Nasdaq stockholders' equity compliance; bid price issue unresolved
Received Nasdaq confirmation on June 6, 2025 that it regained compliance with stockholders' equity requirement of $2.5M.
New SRA with Pitt for preclinical studies of GPX-002 in T1D and T2D animal models.
Genprex licenses NYU patent for Reqorsa gene therapy in mesothelioma; TUSC2 down in 84%
Exclusive patent license with NYU Langone Health for Reqorsa (quaratusugene ozeplasmid) to treat mesothelioma.
Entered amended and restated exclusive license with Univ of Pittsburgh for T1D and T2D gene therapy using Pdx1 and MafA genes.
Genprex receives Nasdaq deficiency notices for bid price and equity requirements
Nasdaq notified Genprex on Feb 7, 2025 that its stock closed below $1.00 for 30 consecutive business days, non-compliant with Rule 5550(a)(2).
Phase 2 expansion will enroll ~50 patients at 10-15 U.S. sites; primary endpoint is 18-week progression-free survival rate.
Genprex completes Phase 1 dose escalation of Reqorsa + Tecentriq in ES-SCLC; Phase 2 opens
No dose-limiting toxicities observed; RP2D set at 0.12 mg/kg (highest dose tested).
Genprex receives Nasdaq delisting notice for failing minimum stockholders' equity requirement
Stockholders' equity of $1,664,971 as of Sept 30, 2024, below the Nasdaq minimum of $2.5 million.
Genprex regains Nasdaq minimum bid price compliance; delisting risk resolved
Received Nasdaq letter on Nov 4, 2024 confirming compliance with Listing Rule 5550(a)(2).
Mr. Confer’s title change to President, Chief Executive Officer and Chief Financial Officer was confirmed
Catherine Vaczy, the Company’s then Executive Vice President, General Counsel and Chief Strategy Officer, notified the Company of her intention to resign.
the Board appointed Ryan Confer, Chief Financial Officer of Genprex since 2016, to serve as President and Chief Executive Officer of Genprex (in addition to his position as Chief Financial Officer of Genprex), effective immediately
On May 8, 2024, Mr. Confer was also appointed to the Board as a Class III director to fill the vacancy caused by Mr. Varner’s passing
Rodney Varner, the Company’s President and Chief Executive Officer and Chairman of the Company’s Board of Directors (the “Board”), passed away unexpectedly on May 7, 2024 due to complications from an ongoing illness.
the Board has determined that Mr. Confer can and shall act alone in covering when Mr. Varner is unavailable.
Catherine Vaczy, the Executive Vice President, General Counsel and Chief Strategy Officer of Genprex, Inc. (“Genprex” or the “Company”) notified the Company of her intention to resign. On February 4, 2024, Ms. Vaczy’s employment with the Company was terminated.
On January 30, 2024, Catherine Vaczy provided Genprex, Inc. (“Genprex” or the “Company”) with a notice of her intention to resign pursuant to Section 7.4 of her Executive Employment Agreement
Effective as of October 15, 2021, Michael Redman’s employment with Genprex, Inc. (the “Company”) as Chief Operating Officer and Executive Vice President of the Company was terminated.
With these new appointments, Michael Redman, the Company’s Executive Vice President and Chief Operating Officer is no longer overseeing the Company’s clinical and manufacturing operations.
the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.
the Company has appointed Mark Berger, MD and Hemant Kumar, PhD as its new Chief Medical Officer and new Chief Manufacturing and Technology Officer, respectively.
Max materiality 0.85 · Median 0.60 · Most common event other_material